Drugs / QBS10072S
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04430842 | Jul 2020 → Sep 2022 | astrocytoma (excluding glioblastoma), breast cancer, cervical cancer, cholangiocarcinoma +15 | Quadriga Biosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02977780 | Feb 2017 → Feb 2028 expected | glioblastoma | Patrick Wen, MD | Recruiting | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QBS10072S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04430842 ↗ |
| Route | Intravenous | “Intravenous administration of QBS10072S once every 4 weeks starting at 3mg/m2 and increasing dose levels in subsequent cohorts.” NCT04430842 ↗ |